LB Pharmaceuticals (LBRX) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
LB Pharmaceuticals (LBRX) has outperformed MeiraGTx (MGTX) over the past year, gaining 130.1% versus a gain of 27.1%. LB Pharmaceuticals is the larger company by market cap ($1.21 billion vs $1.03 billion), about 1.2 times the size. On valuation, MeiraGTx trades at a lower trailing P/E (12.4x vs 375.4x for LB Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LBRX | MGTX |
|---|---|---|
| Share price | $37.54 | $10.75 |
| Market cap | $1.21B | $1.03B |
| 1-day change | +8.47% | +2.38% |
| YTD return | +55.48% | +32.08% |
| 1-year return | +130.12% | +27.12% |
| 5-year return | — | -26.47% |
| P/E ratio (TTM) | 375.40 | 12.36 |
| EPS (TTM) | $0.10 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.16 | $15.35 |
| 52-week low | $14.32 | $6.62 |
| Distance from 52-week high | -25.16% | -29.97% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +52.64% | +158.14% |
| Average volume | 344.34K | 792.38K |
| Shares outstanding | 32.26M | 96.04M |
| Employees | 49 | 393 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LBRX has outperformed MGTX by 103.0 percentage points over the past year.
- LB Pharmaceuticals trades at a higher earnings multiple (375.4x vs 12.4x trailing P/E).
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
LBRX vs MGTX FAQ
Which is bigger, LB Pharmaceuticals or MeiraGTx?
LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.21B compared with $1.03B for MeiraGTx (MGTX).
Which stock has performed better over the past year, LBRX or MGTX?
LBRX returned +130.12% over the past 12 months, compared with +27.12% for MGTX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, LBRX or MGTX?
MGTX has the lower trailing P/E at 12.4, versus 375.4 for LBRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are LB Pharmaceuticals and MeiraGTx in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for LB Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for MeiraGTx.